CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Archive Press releases

01/15/2014

CHEPLAPHARM continues its rapid growth: 50% sales increase in 2013 compared to the previous year.

more chevron_right
Archive

12/31/2012

CHEPLAPHARM acquires the rights for VESANOID® and ROHYPNOL® - largest investment since company´s existence.

more chevron_right
Archive

09/01/2010

CHEPLAPHARM attains the rights for HEMINEVRIN®/DISTRANEURIN®

more chevron_right

Investor Relations topics

Back to top expand_less